Ann: Phase 2 Stroke Clinical Trial Update, page-12

Key point to note from her message - medical people are generally very conservative with their language so to be "extremely positive" shows very high confidence in trial protocol and potential efficacy of our drug:

Dr Liz Dallimore, Managing Director of Argenica, stated “We are delighted with the progress of the Phase 2 trial to date. We are very encouraged by the fact that recruitment is progressing well and the investigators at the hospitals that have recruited patients have all been extremely positive about the study protocol. We look forward to having all trial sites activated and recruiting patients in the coming weeks, which will give us greater clarity on patient recruitment rates and when we can expect to complete the study. We will continue to provide trial updates as recruitment of patients progresses.

Excellent news....Liz and her team are delivering based on the expectations of the company!